1. nAMD: New Drugs and Practice Patterns to Improve Patient Outcomes

3. This program may include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Introduction

5. Limitations of Current Approaches

6. Unmet Needs of Anti-VEGF Therapy

7. Current Anti-VEGF Therapy for nAMD: Limitations

8. Desired Attributes of New Treatments

9. Seven-Year Outcomes in Ranibizumab-Treated Patients: A Multicenter Cohort Study (SEVEN-UP)

10. Observational Study of FRB Database Eyes: Adherence to Treatment May Improve Results

11. Complete Polyp Regression: EVEREST and PLANET Studies at Month 12

12. New Treatments in Development

13. Molecular Sizes of Anti-VEGF Agents

14. Brolucizumab Phase 3 Studies in nAMD: HAWK and HARRIER Studies

15. HAWK and HARRIER Studies: Brolucizumab Reduced Dosing Frequency

16. HAWK/HARRIER: Primary and Sensitivity Analyses

17. Brolucizumab Met The Primary Endpoint of Non-Inferiority in Change in BCVA From Baseline to Week 48

18. HAWK and HARRIER Studies: Anatomical Results at Week 16

19. Significantly Fewer Patients on Brolucizumab Had IRF and/or SRF at Week 16 and Week 48

20. Polypoidal Choroidal Vasculopathy

21. Designed Ankyrin Repeat Protein (DARPin®): Abicipar Pegol

22. Abicipar Pegol: REACH Phase 2 Clinical Study Visual Acuity Results

23. RG7716 Phase 1 Safety/Tolerability and Efficacy Summary Treatment Refractory Patients With Average Disease Duration of 2.9 Years

24. Phase 2 Studies Using RG7716

25. Desired Attributes of New Treatments

26. EVEREST II Change in BCVA of the Study Eye: Treatment Comparison at Months 12 and 24

27. EVEREST II Complete Polyp Regression: Treatment Comparison at Months 12 and 24

28. Conclusions

29. Abbreviations

30. Abbreviations (cont)